New Policies for Buprenorphine Treatment

<p>Following the recent announcement of changes by the Federal Government in policies regarding the use of Buprenorphine, an antagonist medication used in addiction treatment, <a href= "https://www.opiates.com/clare-waismann/" target="_blank" rel= "noopener" data-saferedirecturl= "https://www.google.com/url?q=https://www.opiates.com/clare-waismann/&source=gmail&ust=1621094133465000&usg=AFQjCNGjXK7aTkPfeDHUUOCunK2Mc0lmmg">Clare Waismann, RAS/SUDCC</a> and <a href= "https://www.opiates.com/david-livingston/" target="_blank" rel= "noopener" data-saferedirecturl= "https://www.google.com/url?q=https://www.opiates.com/david-livingston/&source=gmail&ust=1621094133465000&usg=AFQjCNESVr7R_RFI-4PzHoGCTdNVY5ZMyA">David Livingston, LMFT</a> felt it was important to discuss a reaction to the changes and share it with the podcast listeners. The conversation addresses information about what Buprenorphine is, how it is used, pros and cons in our experience, and what these changes can mean for treatment. As always our discussion really centers around making treatment meaningful and effective on the individual level with the people we are here to help. </p> <p>--------------------</p> <p>Send us your questions <a href= "mailto:info@opiates">info@opiates.com </a></p>